Trends in Resource Utilization Associated with the Inpatient Treatment of Neonatal Congenital Heart Disease

Congenital Heart Disease

Volumn 9, Issue 2, 2014, Pages 96-105

  Smith, Andrew H ^a   Gay, James C ^a   Patel, Neal R ^a  

^a MONROE CARELL JR CHILDREN S HOSPITAL AT VANDERBILT   (United States)

Author keywords

Congenital; Cost and Cost Analysis; Health Resources; Heart Defects; Pediatrics

Indexed keywords

BLOOD CLOTTING FACTOR 7A; CHLOROTHIAZIDE; ENOXAPARIN; FLUCONAZOLE; HUMAN ALBUMIN; METHADONE; NITRIC OXIDE; PALIVIZUMAB; PIPERACILLIN PLUS TAZOBACTAM; PROSTAGLANDIN E1;

AORTA COARCTATION; ARTICLE; CASE MIX; CONGENITAL HEART DISEASE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; GREAT VESSELS TRANSPOSITION; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL INFORMATION SYSTEM; MORTALITY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEWBORN; NEWBORN DISEASE; PRIORITY JOURNAL; RISK ADJUSMENT IN CONGENITAL HEART SURGERY; COST; DIAGNOSTIC IMAGING; DRUG COST; ECONOMICS; HEALTH CARE PLANNING; HEALTH CARE QUALITY; HEART DEFECTS, CONGENITAL; HEART SURGERY; HOSPITAL COST; INFANT; INFANT MORTALITY; RETROSPECTIVE STUDY; TIME; TREATMENT OUTCOME; TRENDS; UNITED STATES; UTILIZATION;

CARDIAC SURGICAL PROCEDURES; COSTS AND COST ANALYSIS; DIAGNOSTIC IMAGING; DRUG COSTS; HEALTH EXPENDITURES; HEALTH RESOURCES; HEART DEFECTS, CONGENITAL; HOSPITAL COSTS; HOSPITAL MORTALITY; HUMANS; INFANT; INFANT MORTALITY; INFANT, NEWBORN; INPATIENTS; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); QUALITY OF HEALTH CARE; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84897577519     PISSN: 1747079X     EISSN: 17470803     Source Type: Journal    
DOI: 10.1111/chd.12103     Document Type: Article

References (22)

1. Pasquali SK, Sun J-L, D'Almada P, etal. Center variation in hospital costs for patients undergoing congenital heart surgery. Circ Cardiovasc Qual Outcomes. 2011;4:306-312.
2. Gray D, Pourmoghadam K, Weis J, etal. Nationwide trends in inpatient cardiac surgery and interventional catheterization procedures from 1997-2006: on-line estimates from the US Healthcare Cost and Utilization Project. Circ Cardiovasc Qual Outcomes. 2009;2:e23.
3. Ungerleider RM, Bengur AR, Kessenich AL, etal. Risk factors for higher cost in congenital heart operations. Ann Thorac Surg. 1997;64:44-48; discussion 49.
4. Dean PN, Hillman DG, McHugh KE, Gutgesell HP. Inpatient costs and charges for surgical treatment of hypoplastic left heart syndrome. Pediatrics. 2011;128:e1181-e1186.
5. Institute of Medicine. Better Care at Lower Cost: The Path to Continuously Learning Health Care in America. Washington, D.C.: National Academies Press; 2012.
6. Kim YY, Gauvreau K, Bacha EA, Landzberg MJ, Benavidez OJ. Resource use among adult congenital heart surgery admissions in pediatric hospitals: risk factors for high resource utilization and association with inpatient death. Circ Cardiovasc Qual Outcomes. 2011;4:634-639.
7. Checchia PA, McCollegan J, Daher N, Kolovos N, Levy F, Markovitz B. The effect of surgical case volume on outcome after the Norwood procedure. J Thorac Cardiovasc Surg. 2005;129:754-759.
8. Muldoon JH. Structure and performance of different DRG classification systems for neonatal medicine. Pediatrics. 1999;103:302-318.
9. Averill RF, Goldfield NI, Muldoon J, Steinbeck BA, Grant TM. A closer look at all-patient refined DRGs. J AHIMA. 2002;73:46-50.
10. Bureau of Labor Statistics. CPI Inflation Calculator [Internet]. CPI Inflation Calculator. 2012. Available at: http://www.bls.gov/data/inflation_calculator.htm. Accessed January 3, 2013.
11. Bunn F, Trivedi D. Colloid solutions for fluid resuscitation. Cochrane Database Syst Rev. 2012;(7):CD001319.
12. Perel P, Roberts I. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev. 2012;(6):CD000567.
13. Goldbloom A. At What Cost?: Egregious Price increases in the Pharmaceutical Drug Industry. 2008.
14. Guzzetta NA, Russell IA, Williams GD. Review of the off-label use of recombinant activated factor VII in pediatric cardiac surgery patients. Anesth Analg. 2012;115:364-378.
15. Yank V, Tuohy CV, Logan AC, etal. Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Ann Intern Med. 2011;154:529-540.
16. Pychyńska-Pokorska M, Pagowska-Klimek I, Krajewski W, Moll JJ. Use of recombinant activated factor VII for controlling refractory postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 2011;25:987-994.
17. Karsies TJ, Nicol KK, Galantowicz ME, Stephens JA, Kerlin BA. Thrombotic risk of recombinant factor seven in pediatric cardiac surgery: a single institution experience. Ann Thorac Surg. 2010;89:570-576.
18. Guzzetta NA, Huch S, Fernandez JD, Tosone SR, Miller BE. Use of recombinant factor VIIa for uncontrolled bleeding in neonates after cardiopulmonary bypass. Paediatr Anaesth. 2009;19:364-370.
19. Witmer CM, Huang Y-S, Lynch K, Raffini LJ, Shah SS. Off-label recombinant factor VIIa use and thrombosis in children: a multi-center cohort study. J Pediatr. 2011;158:820-825.
20. Uber WE, Toole JM, Stroud MR, etal. Administration of recombinant activated factor VII in the intensive care unit after complex cardiovascular surgery: clinical and economic outcomes. J Thorac Cardiovasc Surg. 2011;141:1469-1477.
21. Pearlman AS, Ryan T, Picard MH, Douglas PS. Evolving trends in the use of echocardiography: a study of Medicare beneficiaries. J Am Coll Cardiol. 2007;49:2283-2291.
22. Shah BR, Cowper PA, O'Brien SM, etal. Association between physician billing and cardiac stress testing patterns following coronary revascularization. JAMA. 2011;306:1993-2000.